Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. (Q47954857)
Jump to navigation
Jump to search
scientific article published in August 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. |
scientific article published in August 2013 |
Statements
1 reference
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. (English)
1 reference
J Crown
1 reference
M J Kennedy
1 reference
P Tresca
1 reference
M Marty
1 reference
M Espie
1 reference
H A Burris
1 reference
M DeSilvio
1 reference
M R Lau
1 reference
D Kothari
1 reference
K M Koch
1 reference
V Diéras
1 reference
1 August 2013
1 reference
1 reference
24
1 reference
8
1 reference
2005-2011
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference